
iRhythm Unveils Next Generation Zio Monitor and Long-Term Continuous Monitoring Service
iRhythm Technologies, Inc. has unveiled its next-generation Zio® monitor, marking its U.S. launch alongside the enhanced Zio® long-term continuous monitoring (LTCM) service. The Zio monitor, a prescription-only electrocardiogram monitor, is the smallest, lightest, and thinnest cardiac monitor by iRhythm, offering an improved experience for both patients and healthcare providers. The Zio LTCM service encompasses the Zio monitor, ZEUS (Zio ECG Utilization Software) System powered by advanced AI, and comprehensive end-of-wear reports reviewed by certified cardiographic technicians, boasting a 99% physician agreement rate. The new Zio monitor is designed to enhance diagnostic yield and provider efficiency while ensuring an optimal patient experience. It features a 23% reduction in thickness, 62% lighter weight, and a 72% smaller form-factor compared to its predecessor. With up to 14 days of continuous wear, the Zio monitor achieves a 99% patient compliance with prescribed wear times. Moreover, it offers breathability, hydrocolloid adhesive, waterproof housing, and requires no device or adhesive manipulation or battery changes throughout the 14-day monitoring period.
In conjunction with the Zio monitor, iRhythm has launched the redesigned MyZio® patient app, incorporating a new user interface and various enhancements for an improved patient experience. These enhancements include simplified symptom logging, educational content, and an enhanced help center. The Zio LTCM service is covered by numerous commercial insurance companies, including Medicare. iRhythm has introduced enhancements to patient support processes to assist patients in navigating insurance coverage queries and pre-authorizations.
iRhythm’s advanced AI boasts FDA clearance and clinical proof of its accuracy, aligning with expert cardiologists. The CAMELOT study, presented at the American College of Cardiology’s Annual Scientific Session, demonstrated that the Zio LTCM service, with up to 14 days of monitoring, outperformed other monitoring services in diagnostic yield, retesting likelihood, and acute care hospitalization likelihood.
The Zio monitor and LTCM service offer a crucial tool for physicians to better identify, diagnose, and manage cardiac arrhythmias. These conditions affect up to 5% of the U.S. population and can lead to severe health issues if left untreated. The company sold over 1.5 million monitors in calendar year 2022 with double-digit prescriber growth. Based upon a recent investor day held on September 21, 2023, the company is exploring additional indications for its technology including sleep apnea, heart failure, and hypertension.
Zio monitor shipments have commenced, with widespread availability in U.S. clinics expected by early 2024.